Tepezza
Tepezza is a drug to treat Thyroid Eye Disease (TED).
It was approved by the FDA in 2020, but the manufacturers, Horizon Therapeutics, failed to warn of the drug’s potential to cause serious and permanent hearing loss.
Clinical testing submitted to the FDA for Tepezza consisted of just two trials, with only 84 patients taking the brand-new compound.
Reports of hearing loss in the trials were represented as “temporary and generally of limited duration.”
Scientific studies in recent times have found that a high percentage of patients who took the drug have suffered potentially permanent hearing loss. Despite claiming that hearing loss associated with Tepezza was “temporary and generally of limited duration,” scientific research has shown that the infusions can actually result in the following hearing problems:
- Permanent hearing loss
- Partial hearing loss
- Tinnitus (ringing in the ears)
- Sensorineural hearing loss
- Patulous Eustachian Tube Dysfunction
- Increased sensitivity to sound
- A sensation of the ears feeling full or plugged
We are seeking compensation for anyone who was affected by the negligence of Horizon Therapeutics.
Pogust Goodhead has decades of combined experience in pharmaceutical, product liability and mass tort claims, and are well-suited to assist you in investigating a possible lawsuit.
Our firm does not take a fee unless you recover a settlement or verdict, and you could be owed significant compensation.
If you have ever used Tepezza and think you may have been affected, please apply now for an evaluation of your potential claim.
The Team
Other Cases
Diesel Emissions Fraud
Pogust Goodhead is taking action against vehicle manufacturers that have been accused of malpractice to hold them to account.
Mariana Dam Disaster
The worst environmental disaster in Brazil’s history has triggered one of the biggest legal claims ever filed in the Courts of England and Wales: the Mariana dam disaster claim.
NHS Lothian Audiology
In December 2021, an audit report by the British Academy of Audiology showed significant failures in NHS Lothian’s Paediatric Audiology Service.